Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

Melody B Oncale, Hossein Maymani, Loretta J Nastoupil Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oncale MB, Maymani H, Nastoupil LJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Hodgkin lymphoma programmed death-1 Nivolumab pembrolizumab lymphoma Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/0ba68679533d455ca73fb5c9cf5a71ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ba68679533d455ca73fb5c9cf5a71ab
record_format	dspace
spelling	oai:doaj.org-article:0ba68679533d455ca73fb5c9cf5a71ab2021-12-02T00:39:43ZHarnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma1179-9889https://doaj.org/article/0ba68679533d455ca73fb5c9cf5a71ab2017-02-01T00:00:00Zhttps://www.dovepress.com/harnessing-the-immune-system-through-programmed-death-1-blockade-in-th-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Melody B Oncale, Hossein Maymani, Loretta J Nastoupil Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system’s ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system’s ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents. Keywords: Hodgkin lymphoma, programmed death-1, nivolumab, pembrolizumab, lymphomaOncale MBMaymani HNastoupil LJDove Medical PressarticleHodgkin lymphomaprogrammed death-1NivolumabpembrolizumablymphomaDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 7, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Hodgkin lymphoma programmed death-1 Nivolumab pembrolizumab lymphoma Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Hodgkin lymphoma programmed death-1 Nivolumab pembrolizumab lymphoma Diseases of the blood and blood-forming organs RC633-647.5 Oncale MB Maymani H Nastoupil LJ Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
description	Melody B Oncale, Hossein Maymani, Loretta J Nastoupil Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system’s ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system’s ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents. Keywords: Hodgkin lymphoma, programmed death-1, nivolumab, pembrolizumab, lymphoma
format	article
author	Oncale MB Maymani H Nastoupil LJ
author_facet	Oncale MB Maymani H Nastoupil LJ
author_sort	Oncale MB
title	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
title_short	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
title_full	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
title_fullStr	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
title_full_unstemmed	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
title_sort	harnessing the immune system through programmed death-1 blockade in the management of hodgkin lymphoma
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/0ba68679533d455ca73fb5c9cf5a71ab
work_keys_str_mv	AT oncalemb harnessingtheimmunesystemthroughprogrammeddeath1blockadeinthemanagementofhodgkinlymphoma AT maymanih harnessingtheimmunesystemthroughprogrammeddeath1blockadeinthemanagementofhodgkinlymphoma AT nastoupillj harnessingtheimmunesystemthroughprogrammeddeath1blockadeinthemanagementofhodgkinlymphoma
_version_	1718403537609687040

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

Ejemplares similares